Sphingolipids in lung endothelial biology and regulation of vascular integrity

Taimur Abbasi, Joe GN Garcia

Research output: Chapter in Book/Report/Conference proceedingChapter

30 Citations (Scopus)

Abstract

Of the multiple and diverse homeostatic events that involve the lung vascular endothelium, participation in preserving vascular integrity and therefore organ function is paramount. We were the first to show that the lipid growth factor and angiogenic factor, sphingosine-1-phosphate, is a critical agonist involved in regulation of human lung vascular barrier function (Garcia et al. J Clin Invest, 2011). Utilizing both in vitro models and preclinical murine, rat, and canine models of acute and chronic inflammatory lung injury, we have shown that S1Ps, as well as multiple S1P analogues such as FTY720 and ftysiponate, serve as protective agents limiting the disruption of the vascular EC monolayer in the pulmonary microcirculation and attenuate parenchymal accumulation of inflammatory cells and high protein containing extravasated fluid, thereby reducing interstitial and alveolar edema. The vasculo-protective mechanism of these therapeutic effects occurs via ligation of specific G-protein-coupled receptors and an intricate interplay of S1P with other factors (such asMAPKS, ROCKs, Rho, Rac1) with rearrangement of the endothelial cytoskeleton to form strong cortical actin rings in the cell periphery and enhanced cell-to-cell and cell-to-matrix tethering dynamics. This cascade leads to reinforcement of focal adhesions and paracellular junctional complexes via cadherin, paxillin, catenins, and zona occludens. S1P through its interaction with Rac and Rho influences the cytoskeletal rearrangement indicated in the later stages of angiogenesis as a stabilizing force, preventing excessive vascular permeability. These properties translate into a therapeutic potential for acute and chronic inflammatory lung injuries. S1P has potential for providing a paradigm shift in the approach to disruption of critical endothelial gatekeeper function, loss of lung vascular integrity, and increased vascular permeability, defining features of acute lung injury (ALI), and may prove to exhibit an intrinsically protective role in the pulmonary vasculature ameliorating agonist- or sepsis-induced pulmonary injury and vascular leakage.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
Pages201-226
Number of pages26
Volume216
DOIs
StatePublished - 2013
Externally publishedYes

Publication series

NameHandbook of Experimental Pharmacology
Volume216
ISSN (Print)01712004
ISSN (Electronic)18650325

Fingerprint

Sphingolipids
Blood Vessels
Lung Injury
Lung
Paxillin
Microcirculation
Capillary Permeability
Protective Agents
Catenins
Angiogenesis Inducing Agents
Cadherins
G-Protein-Coupled Receptors
Rats
Actins
Monolayers
Intercellular Signaling Peptides and Proteins
Reinforcement
Adhesion
Cells
Focal Adhesions

Keywords

  • Cytoskeleton
  • Endothelial cells
  • Rac
  • Rho
  • S1p

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry

Cite this

Abbasi, T., & Garcia, J. GN. (2013). Sphingolipids in lung endothelial biology and regulation of vascular integrity. In Handbook of Experimental Pharmacology (Vol. 216, pp. 201-226). (Handbook of Experimental Pharmacology; Vol. 216). https://doi.org/10.1007/978-3-7091-1511-4-10

Sphingolipids in lung endothelial biology and regulation of vascular integrity. / Abbasi, Taimur; Garcia, Joe GN.

Handbook of Experimental Pharmacology. Vol. 216 2013. p. 201-226 (Handbook of Experimental Pharmacology; Vol. 216).

Research output: Chapter in Book/Report/Conference proceedingChapter

Abbasi, T & Garcia, JGN 2013, Sphingolipids in lung endothelial biology and regulation of vascular integrity. in Handbook of Experimental Pharmacology. vol. 216, Handbook of Experimental Pharmacology, vol. 216, pp. 201-226. https://doi.org/10.1007/978-3-7091-1511-4-10
Abbasi T, Garcia JGN. Sphingolipids in lung endothelial biology and regulation of vascular integrity. In Handbook of Experimental Pharmacology. Vol. 216. 2013. p. 201-226. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/978-3-7091-1511-4-10
Abbasi, Taimur ; Garcia, Joe GN. / Sphingolipids in lung endothelial biology and regulation of vascular integrity. Handbook of Experimental Pharmacology. Vol. 216 2013. pp. 201-226 (Handbook of Experimental Pharmacology).
@inbook{933af02bdbf240afa583529c1eef8536,
title = "Sphingolipids in lung endothelial biology and regulation of vascular integrity",
abstract = "Of the multiple and diverse homeostatic events that involve the lung vascular endothelium, participation in preserving vascular integrity and therefore organ function is paramount. We were the first to show that the lipid growth factor and angiogenic factor, sphingosine-1-phosphate, is a critical agonist involved in regulation of human lung vascular barrier function (Garcia et al. J Clin Invest, 2011). Utilizing both in vitro models and preclinical murine, rat, and canine models of acute and chronic inflammatory lung injury, we have shown that S1Ps, as well as multiple S1P analogues such as FTY720 and ftysiponate, serve as protective agents limiting the disruption of the vascular EC monolayer in the pulmonary microcirculation and attenuate parenchymal accumulation of inflammatory cells and high protein containing extravasated fluid, thereby reducing interstitial and alveolar edema. The vasculo-protective mechanism of these therapeutic effects occurs via ligation of specific G-protein-coupled receptors and an intricate interplay of S1P with other factors (such asMAPKS, ROCKs, Rho, Rac1) with rearrangement of the endothelial cytoskeleton to form strong cortical actin rings in the cell periphery and enhanced cell-to-cell and cell-to-matrix tethering dynamics. This cascade leads to reinforcement of focal adhesions and paracellular junctional complexes via cadherin, paxillin, catenins, and zona occludens. S1P through its interaction with Rac and Rho influences the cytoskeletal rearrangement indicated in the later stages of angiogenesis as a stabilizing force, preventing excessive vascular permeability. These properties translate into a therapeutic potential for acute and chronic inflammatory lung injuries. S1P has potential for providing a paradigm shift in the approach to disruption of critical endothelial gatekeeper function, loss of lung vascular integrity, and increased vascular permeability, defining features of acute lung injury (ALI), and may prove to exhibit an intrinsically protective role in the pulmonary vasculature ameliorating agonist- or sepsis-induced pulmonary injury and vascular leakage.",
keywords = "Cytoskeleton, Endothelial cells, Rac, Rho, S1p",
author = "Taimur Abbasi and Garcia, {Joe GN}",
year = "2013",
doi = "10.1007/978-3-7091-1511-4-10",
language = "English (US)",
isbn = "9783709115107",
volume = "216",
series = "Handbook of Experimental Pharmacology",
pages = "201--226",
booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - Sphingolipids in lung endothelial biology and regulation of vascular integrity

AU - Abbasi, Taimur

AU - Garcia, Joe GN

PY - 2013

Y1 - 2013

N2 - Of the multiple and diverse homeostatic events that involve the lung vascular endothelium, participation in preserving vascular integrity and therefore organ function is paramount. We were the first to show that the lipid growth factor and angiogenic factor, sphingosine-1-phosphate, is a critical agonist involved in regulation of human lung vascular barrier function (Garcia et al. J Clin Invest, 2011). Utilizing both in vitro models and preclinical murine, rat, and canine models of acute and chronic inflammatory lung injury, we have shown that S1Ps, as well as multiple S1P analogues such as FTY720 and ftysiponate, serve as protective agents limiting the disruption of the vascular EC monolayer in the pulmonary microcirculation and attenuate parenchymal accumulation of inflammatory cells and high protein containing extravasated fluid, thereby reducing interstitial and alveolar edema. The vasculo-protective mechanism of these therapeutic effects occurs via ligation of specific G-protein-coupled receptors and an intricate interplay of S1P with other factors (such asMAPKS, ROCKs, Rho, Rac1) with rearrangement of the endothelial cytoskeleton to form strong cortical actin rings in the cell periphery and enhanced cell-to-cell and cell-to-matrix tethering dynamics. This cascade leads to reinforcement of focal adhesions and paracellular junctional complexes via cadherin, paxillin, catenins, and zona occludens. S1P through its interaction with Rac and Rho influences the cytoskeletal rearrangement indicated in the later stages of angiogenesis as a stabilizing force, preventing excessive vascular permeability. These properties translate into a therapeutic potential for acute and chronic inflammatory lung injuries. S1P has potential for providing a paradigm shift in the approach to disruption of critical endothelial gatekeeper function, loss of lung vascular integrity, and increased vascular permeability, defining features of acute lung injury (ALI), and may prove to exhibit an intrinsically protective role in the pulmonary vasculature ameliorating agonist- or sepsis-induced pulmonary injury and vascular leakage.

AB - Of the multiple and diverse homeostatic events that involve the lung vascular endothelium, participation in preserving vascular integrity and therefore organ function is paramount. We were the first to show that the lipid growth factor and angiogenic factor, sphingosine-1-phosphate, is a critical agonist involved in regulation of human lung vascular barrier function (Garcia et al. J Clin Invest, 2011). Utilizing both in vitro models and preclinical murine, rat, and canine models of acute and chronic inflammatory lung injury, we have shown that S1Ps, as well as multiple S1P analogues such as FTY720 and ftysiponate, serve as protective agents limiting the disruption of the vascular EC monolayer in the pulmonary microcirculation and attenuate parenchymal accumulation of inflammatory cells and high protein containing extravasated fluid, thereby reducing interstitial and alveolar edema. The vasculo-protective mechanism of these therapeutic effects occurs via ligation of specific G-protein-coupled receptors and an intricate interplay of S1P with other factors (such asMAPKS, ROCKs, Rho, Rac1) with rearrangement of the endothelial cytoskeleton to form strong cortical actin rings in the cell periphery and enhanced cell-to-cell and cell-to-matrix tethering dynamics. This cascade leads to reinforcement of focal adhesions and paracellular junctional complexes via cadherin, paxillin, catenins, and zona occludens. S1P through its interaction with Rac and Rho influences the cytoskeletal rearrangement indicated in the later stages of angiogenesis as a stabilizing force, preventing excessive vascular permeability. These properties translate into a therapeutic potential for acute and chronic inflammatory lung injuries. S1P has potential for providing a paradigm shift in the approach to disruption of critical endothelial gatekeeper function, loss of lung vascular integrity, and increased vascular permeability, defining features of acute lung injury (ALI), and may prove to exhibit an intrinsically protective role in the pulmonary vasculature ameliorating agonist- or sepsis-induced pulmonary injury and vascular leakage.

KW - Cytoskeleton

KW - Endothelial cells

KW - Rac

KW - Rho

KW - S1p

UR - http://www.scopus.com/inward/record.url?scp=84880538151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880538151&partnerID=8YFLogxK

U2 - 10.1007/978-3-7091-1511-4-10

DO - 10.1007/978-3-7091-1511-4-10

M3 - Chapter

C2 - 23563658

AN - SCOPUS:84880538151

SN - 9783709115107

VL - 216

T3 - Handbook of Experimental Pharmacology

SP - 201

EP - 226

BT - Handbook of Experimental Pharmacology

ER -